nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—CYP3A4—Bexarotene—hematologic cancer	0.0558	0.0829	CbGbCtD
Fosamprenavir—CYP3A4—Lomustine—hematologic cancer	0.0519	0.0771	CbGbCtD
Fosamprenavir—CYP3A4—Busulfan—hematologic cancer	0.0519	0.0771	CbGbCtD
Fosamprenavir—CYP3A4—Thiotepa—hematologic cancer	0.0462	0.0687	CbGbCtD
Fosamprenavir—CYP3A4—Methoxsalen—hematologic cancer	0.0359	0.0534	CbGbCtD
Fosamprenavir—CYP3A4—Bortezomib—hematologic cancer	0.0342	0.0508	CbGbCtD
Fosamprenavir—CYP3A4—Daunorubicin—hematologic cancer	0.0327	0.0486	CbGbCtD
Fosamprenavir—CYP3A4—Cytarabine—hematologic cancer	0.0288	0.0429	CbGbCtD
Fosamprenavir—CYP3A4—Teniposide—hematologic cancer	0.0284	0.0422	CbGbCtD
Fosamprenavir—CYP3A4—Ifosfamide—hematologic cancer	0.0262	0.039	CbGbCtD
Fosamprenavir—CYP3A4—Imatinib—hematologic cancer	0.025	0.0372	CbGbCtD
Fosamprenavir—CYP3A4—Ruxolitinib—hematologic cancer	0.0236	0.0351	CbGbCtD
Fosamprenavir—CYP3A4—Nilotinib—hematologic cancer	0.0228	0.0338	CbGbCtD
Fosamprenavir—CYP3A4—Vinorelbine—hematologic cancer	0.0226	0.0335	CbGbCtD
Fosamprenavir—CYP3A4—Triamcinolone—hematologic cancer	0.0206	0.0307	CbGbCtD
Fosamprenavir—CYP3A4—Dasatinib—hematologic cancer	0.0201	0.0299	CbGbCtD
Fosamprenavir—CYP3A4—Mitoxantrone—hematologic cancer	0.0199	0.0295	CbGbCtD
Fosamprenavir—CYP3A4—Betamethasone—hematologic cancer	0.0177	0.0263	CbGbCtD
Fosamprenavir—CYP3A4—Prednisolone—hematologic cancer	0.0175	0.026	CbGbCtD
Fosamprenavir—CYP3A4—Prednisone—hematologic cancer	0.0165	0.0245	CbGbCtD
Fosamprenavir—CYP3A4—Irinotecan—hematologic cancer	0.0156	0.0233	CbGbCtD
Fosamprenavir—CYP3A4—Vinblastine—hematologic cancer	0.0139	0.0207	CbGbCtD
Fosamprenavir—CYP3A4—Vincristine—hematologic cancer	0.0137	0.0203	CbGbCtD
Fosamprenavir—CYP3A4—Etoposide—hematologic cancer	0.0125	0.0186	CbGbCtD
Fosamprenavir—CYP3A4—Dexamethasone—hematologic cancer	0.0103	0.0153	CbGbCtD
Fosamprenavir—CYP3A4—Doxorubicin—hematologic cancer	0.00855	0.0127	CbGbCtD
Fosamprenavir—Body temperature increased—Cisplatin—hematologic cancer	9.94e-05	0.000304	CcSEcCtD
Fosamprenavir—Asthenia—Irinotecan—hematologic cancer	9.94e-05	0.000304	CcSEcCtD
Fosamprenavir—Asthenia—Mitoxantrone—hematologic cancer	9.94e-05	0.000304	CcSEcCtD
Fosamprenavir—Fatigue—Etoposide—hematologic cancer	9.93e-05	0.000304	CcSEcCtD
Fosamprenavir—Myalgia—Betamethasone—hematologic cancer	9.89e-05	0.000302	CcSEcCtD
Fosamprenavir—Myalgia—Dexamethasone—hematologic cancer	9.89e-05	0.000302	CcSEcCtD
Fosamprenavir—Vomiting—Thalidomide—hematologic cancer	9.86e-05	0.000302	CcSEcCtD
Fosamprenavir—Dizziness—Carmustine—hematologic cancer	9.85e-05	0.000301	CcSEcCtD
Fosamprenavir—Neutropenia—Doxorubicin—hematologic cancer	9.82e-05	0.0003	CcSEcCtD
Fosamprenavir—Rash—Thalidomide—hematologic cancer	9.78e-05	0.000299	CcSEcCtD
Fosamprenavir—Dermatitis—Thalidomide—hematologic cancer	9.77e-05	0.000299	CcSEcCtD
Fosamprenavir—Haemoglobin—Methotrexate—hematologic cancer	9.76e-05	0.000298	CcSEcCtD
Fosamprenavir—Dizziness—Alitretinoin—hematologic cancer	9.76e-05	0.000298	CcSEcCtD
Fosamprenavir—Diarrhoea—Vincristine—hematologic cancer	9.73e-05	0.000297	CcSEcCtD
Fosamprenavir—Headache—Thalidomide—hematologic cancer	9.72e-05	0.000297	CcSEcCtD
Fosamprenavir—Haemorrhage—Methotrexate—hematologic cancer	9.71e-05	0.000297	CcSEcCtD
Fosamprenavir—Asthenia—Gemcitabine—hematologic cancer	9.68e-05	0.000296	CcSEcCtD
Fosamprenavir—Dizziness—Ifosfamide—hematologic cancer	9.64e-05	0.000295	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Methotrexate—hematologic cancer	9.59e-05	0.000293	CcSEcCtD
Fosamprenavir—Pruritus—Gemcitabine—hematologic cancer	9.54e-05	0.000292	CcSEcCtD
Fosamprenavir—Nausea—Thiotepa—hematologic cancer	9.53e-05	0.000291	CcSEcCtD
Fosamprenavir—Urethral disorder—Methotrexate—hematologic cancer	9.52e-05	0.000291	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	9.52e-05	0.000291	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Doxorubicin—hematologic cancer	9.48e-05	0.00029	CcSEcCtD
Fosamprenavir—Diarrhoea—Irinotecan—hematologic cancer	9.48e-05	0.00029	CcSEcCtD
Fosamprenavir—Diarrhoea—Mitoxantrone—hematologic cancer	9.48e-05	0.00029	CcSEcCtD
Fosamprenavir—Vomiting—Carmustine—hematologic cancer	9.47e-05	0.00029	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Etoposide—hematologic cancer	9.42e-05	0.000288	CcSEcCtD
Fosamprenavir—Dizziness—Vincristine—hematologic cancer	9.4e-05	0.000288	CcSEcCtD
Fosamprenavir—Rash—Carmustine—hematologic cancer	9.39e-05	0.000287	CcSEcCtD
Fosamprenavir—Dermatitis—Carmustine—hematologic cancer	9.38e-05	0.000287	CcSEcCtD
Fosamprenavir—Vomiting—Alitretinoin—hematologic cancer	9.38e-05	0.000287	CcSEcCtD
Fosamprenavir—Headache—Carmustine—hematologic cancer	9.33e-05	0.000285	CcSEcCtD
Fosamprenavir—Rash—Alitretinoin—hematologic cancer	9.3e-05	0.000284	CcSEcCtD
Fosamprenavir—Nervous system disorder—Dexamethasone—hematologic cancer	9.3e-05	0.000284	CcSEcCtD
Fosamprenavir—Nervous system disorder—Betamethasone—hematologic cancer	9.3e-05	0.000284	CcSEcCtD
Fosamprenavir—Dermatitis—Alitretinoin—hematologic cancer	9.3e-05	0.000284	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	9.29e-05	0.000284	CcSEcCtD
Fosamprenavir—Vomiting—Ifosfamide—hematologic cancer	9.27e-05	0.000284	CcSEcCtD
Fosamprenavir—Hypersensitivity—Cisplatin—hematologic cancer	9.26e-05	0.000283	CcSEcCtD
Fosamprenavir—Headache—Alitretinoin—hematologic cancer	9.24e-05	0.000283	CcSEcCtD
Fosamprenavir—Angioedema—Prednisone—hematologic cancer	9.24e-05	0.000283	CcSEcCtD
Fosamprenavir—Diarrhoea—Gemcitabine—hematologic cancer	9.23e-05	0.000282	CcSEcCtD
Fosamprenavir—Nausea—Thalidomide—hematologic cancer	9.21e-05	0.000282	CcSEcCtD
Fosamprenavir—Rash—Ifosfamide—hematologic cancer	9.2e-05	0.000281	CcSEcCtD
Fosamprenavir—Dermatitis—Ifosfamide—hematologic cancer	9.19e-05	0.000281	CcSEcCtD
Fosamprenavir—Erythema multiforme—Methotrexate—hematologic cancer	9.18e-05	0.000281	CcSEcCtD
Fosamprenavir—Dizziness—Irinotecan—hematologic cancer	9.16e-05	0.00028	CcSEcCtD
Fosamprenavir—Haemoglobin—Epirubicin—hematologic cancer	9.13e-05	0.000279	CcSEcCtD
Fosamprenavir—Body temperature increased—Etoposide—hematologic cancer	9.11e-05	0.000278	CcSEcCtD
Fosamprenavir—Abdominal pain—Etoposide—hematologic cancer	9.11e-05	0.000278	CcSEcCtD
Fosamprenavir—Haemorrhage—Epirubicin—hematologic cancer	9.09e-05	0.000278	CcSEcCtD
Fosamprenavir—Vomiting—Vincristine—hematologic cancer	9.04e-05	0.000276	CcSEcCtD
Fosamprenavir—Anorexia—Dexamethasone—hematologic cancer	9.04e-05	0.000276	CcSEcCtD
Fosamprenavir—Anorexia—Betamethasone—hematologic cancer	9.04e-05	0.000276	CcSEcCtD
Fosamprenavir—Asthenia—Cisplatin—hematologic cancer	9.02e-05	0.000276	CcSEcCtD
Fosamprenavir—Cardiac disorder—Methotrexate—hematologic cancer	9.01e-05	0.000276	CcSEcCtD
Fosamprenavir—Fatigue—Triamcinolone—hematologic cancer	9.01e-05	0.000275	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Epirubicin—hematologic cancer	8.98e-05	0.000274	CcSEcCtD
Fosamprenavir—Rash—Vincristine—hematologic cancer	8.97e-05	0.000274	CcSEcCtD
Fosamprenavir—Dermatitis—Vincristine—hematologic cancer	8.96e-05	0.000274	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Epirubicin—hematologic cancer	8.93e-05	0.000273	CcSEcCtD
Fosamprenavir—Urethral disorder—Epirubicin—hematologic cancer	8.91e-05	0.000272	CcSEcCtD
Fosamprenavir—Headache—Vincristine—hematologic cancer	8.91e-05	0.000272	CcSEcCtD
Fosamprenavir—Nausea—Carmustine—hematologic cancer	8.85e-05	0.000271	CcSEcCtD
Fosamprenavir—Vomiting—Irinotecan—hematologic cancer	8.81e-05	0.000269	CcSEcCtD
Fosamprenavir—Vomiting—Mitoxantrone—hematologic cancer	8.81e-05	0.000269	CcSEcCtD
Fosamprenavir—Immune system disorder—Methotrexate—hematologic cancer	8.77e-05	0.000268	CcSEcCtD
Fosamprenavir—Nausea—Alitretinoin—hematologic cancer	8.77e-05	0.000268	CcSEcCtD
Fosamprenavir—Rash—Mitoxantrone—hematologic cancer	8.73e-05	0.000267	CcSEcCtD
Fosamprenavir—Rash—Irinotecan—hematologic cancer	8.73e-05	0.000267	CcSEcCtD
Fosamprenavir—Dermatitis—Mitoxantrone—hematologic cancer	8.72e-05	0.000267	CcSEcCtD
Fosamprenavir—Dermatitis—Irinotecan—hematologic cancer	8.72e-05	0.000267	CcSEcCtD
Fosamprenavir—Headache—Irinotecan—hematologic cancer	8.68e-05	0.000265	CcSEcCtD
Fosamprenavir—Headache—Mitoxantrone—hematologic cancer	8.68e-05	0.000265	CcSEcCtD
Fosamprenavir—Nausea—Ifosfamide—hematologic cancer	8.66e-05	0.000265	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Betamethasone—hematologic cancer	8.64e-05	0.000264	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	8.64e-05	0.000264	CcSEcCtD
Fosamprenavir—Myalgia—Prednisone—hematologic cancer	8.61e-05	0.000263	CcSEcCtD
Fosamprenavir—Diarrhoea—Cisplatin—hematologic cancer	8.6e-05	0.000263	CcSEcCtD
Fosamprenavir—Erythema multiforme—Epirubicin—hematologic cancer	8.59e-05	0.000263	CcSEcCtD
Fosamprenavir—Vomiting—Gemcitabine—hematologic cancer	8.58e-05	0.000262	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.55e-05	0.000262	CcSEcCtD
Fosamprenavir—Rash—Gemcitabine—hematologic cancer	8.51e-05	0.00026	CcSEcCtD
Fosamprenavir—Dermatitis—Gemcitabine—hematologic cancer	8.5e-05	0.00026	CcSEcCtD
Fosamprenavir—Hypersensitivity—Etoposide—hematologic cancer	8.49e-05	0.000259	CcSEcCtD
Fosamprenavir—Malnutrition—Methotrexate—hematologic cancer	8.45e-05	0.000258	CcSEcCtD
Fosamprenavir—Haemoglobin—Doxorubicin—hematologic cancer	8.45e-05	0.000258	CcSEcCtD
Fosamprenavir—Headache—Gemcitabine—hematologic cancer	8.45e-05	0.000258	CcSEcCtD
Fosamprenavir—Nausea—Vincristine—hematologic cancer	8.45e-05	0.000258	CcSEcCtD
Fosamprenavir—Cardiac disorder—Epirubicin—hematologic cancer	8.43e-05	0.000258	CcSEcCtD
Fosamprenavir—Haemorrhage—Doxorubicin—hematologic cancer	8.41e-05	0.000257	CcSEcCtD
Fosamprenavir—Hypersensitivity—Prednisolone—hematologic cancer	8.37e-05	0.000256	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Doxorubicin—hematologic cancer	8.3e-05	0.000254	CcSEcCtD
Fosamprenavir—Asthenia—Etoposide—hematologic cancer	8.26e-05	0.000253	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Doxorubicin—hematologic cancer	8.26e-05	0.000253	CcSEcCtD
Fosamprenavir—Body temperature increased—Triamcinolone—hematologic cancer	8.26e-05	0.000253	CcSEcCtD
Fosamprenavir—Urethral disorder—Doxorubicin—hematologic cancer	8.24e-05	0.000252	CcSEcCtD
Fosamprenavir—Decreased appetite—Dexamethasone—hematologic cancer	8.24e-05	0.000252	CcSEcCtD
Fosamprenavir—Decreased appetite—Betamethasone—hematologic cancer	8.24e-05	0.000252	CcSEcCtD
Fosamprenavir—Nausea—Mitoxantrone—hematologic cancer	8.23e-05	0.000251	CcSEcCtD
Fosamprenavir—Nausea—Irinotecan—hematologic cancer	8.23e-05	0.000251	CcSEcCtD
Fosamprenavir—Immune system disorder—Epirubicin—hematologic cancer	8.21e-05	0.000251	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.18e-05	0.00025	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.18e-05	0.00025	CcSEcCtD
Fosamprenavir—Fatigue—Betamethasone—hematologic cancer	8.17e-05	0.00025	CcSEcCtD
Fosamprenavir—Fatigue—Dexamethasone—hematologic cancer	8.17e-05	0.00025	CcSEcCtD
Fosamprenavir—Pruritus—Etoposide—hematologic cancer	8.15e-05	0.000249	CcSEcCtD
Fosamprenavir—Nervous system disorder—Prednisone—hematologic cancer	8.1e-05	0.000248	CcSEcCtD
Fosamprenavir—Skin disorder—Prednisone—hematologic cancer	8.02e-05	0.000245	CcSEcCtD
Fosamprenavir—Nausea—Gemcitabine—hematologic cancer	8.01e-05	0.000245	CcSEcCtD
Fosamprenavir—Vomiting—Cisplatin—hematologic cancer	7.99e-05	0.000244	CcSEcCtD
Fosamprenavir—Erythema multiforme—Doxorubicin—hematologic cancer	7.95e-05	0.000243	CcSEcCtD
Fosamprenavir—Rash—Cisplatin—hematologic cancer	7.93e-05	0.000242	CcSEcCtD
Fosamprenavir—Dermatitis—Cisplatin—hematologic cancer	7.92e-05	0.000242	CcSEcCtD
Fosamprenavir—Malnutrition—Epirubicin—hematologic cancer	7.91e-05	0.000242	CcSEcCtD
Fosamprenavir—Diarrhoea—Etoposide—hematologic cancer	7.88e-05	0.000241	CcSEcCtD
Fosamprenavir—Anorexia—Prednisone—hematologic cancer	7.87e-05	0.000241	CcSEcCtD
Fosamprenavir—Cardiac disorder—Doxorubicin—hematologic cancer	7.8e-05	0.000239	CcSEcCtD
Fosamprenavir—Flatulence—Epirubicin—hematologic cancer	7.8e-05	0.000238	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Betamethasone—hematologic cancer	7.75e-05	0.000237	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.75e-05	0.000237	CcSEcCtD
Fosamprenavir—Hypersensitivity—Triamcinolone—hematologic cancer	7.7e-05	0.000235	CcSEcCtD
Fosamprenavir—Dizziness—Etoposide—hematologic cancer	7.62e-05	0.000233	CcSEcCtD
Fosamprenavir—Immune system disorder—Doxorubicin—hematologic cancer	7.6e-05	0.000232	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Prednisone—hematologic cancer	7.52e-05	0.00023	CcSEcCtD
Fosamprenavir—Dizziness—Prednisolone—hematologic cancer	7.51e-05	0.00023	CcSEcCtD
Fosamprenavir—Asthenia—Triamcinolone—hematologic cancer	7.5e-05	0.000229	CcSEcCtD
Fosamprenavir—Body temperature increased—Betamethasone—hematologic cancer	7.49e-05	0.000229	CcSEcCtD
Fosamprenavir—Abdominal pain—Dexamethasone—hematologic cancer	7.49e-05	0.000229	CcSEcCtD
Fosamprenavir—Abdominal pain—Betamethasone—hematologic cancer	7.49e-05	0.000229	CcSEcCtD
Fosamprenavir—Body temperature increased—Dexamethasone—hematologic cancer	7.49e-05	0.000229	CcSEcCtD
Fosamprenavir—Nausea—Cisplatin—hematologic cancer	7.47e-05	0.000228	CcSEcCtD
Fosamprenavir—Pruritus—Triamcinolone—hematologic cancer	7.39e-05	0.000226	CcSEcCtD
Fosamprenavir—Vomiting—Etoposide—hematologic cancer	7.32e-05	0.000224	CcSEcCtD
Fosamprenavir—Malnutrition—Doxorubicin—hematologic cancer	7.32e-05	0.000224	CcSEcCtD
Fosamprenavir—Rash—Etoposide—hematologic cancer	7.26e-05	0.000222	CcSEcCtD
Fosamprenavir—Dermatitis—Etoposide—hematologic cancer	7.26e-05	0.000222	CcSEcCtD
Fosamprenavir—Headache—Etoposide—hematologic cancer	7.22e-05	0.000221	CcSEcCtD
Fosamprenavir—Flatulence—Doxorubicin—hematologic cancer	7.21e-05	0.000221	CcSEcCtD
Fosamprenavir—Myalgia—Methotrexate—hematologic cancer	7.2e-05	0.00022	CcSEcCtD
Fosamprenavir—Decreased appetite—Prednisone—hematologic cancer	7.18e-05	0.000219	CcSEcCtD
Fosamprenavir—Rash—Prednisolone—hematologic cancer	7.16e-05	0.000219	CcSEcCtD
Fosamprenavir—Dermatitis—Prednisolone—hematologic cancer	7.16e-05	0.000219	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.15e-05	0.000219	CcSEcCtD
Fosamprenavir—Fatigue—Prednisone—hematologic cancer	7.12e-05	0.000218	CcSEcCtD
Fosamprenavir—Headache—Prednisolone—hematologic cancer	7.12e-05	0.000218	CcSEcCtD
Fosamprenavir—Dizziness—Triamcinolone—hematologic cancer	6.91e-05	0.000211	CcSEcCtD
Fosamprenavir—Nausea—Etoposide—hematologic cancer	6.84e-05	0.000209	CcSEcCtD
Fosamprenavir—Asthenia—Dexamethasone—hematologic cancer	6.8e-05	0.000208	CcSEcCtD
Fosamprenavir—Asthenia—Betamethasone—hematologic cancer	6.8e-05	0.000208	CcSEcCtD
Fosamprenavir—Nervous system disorder—Methotrexate—hematologic cancer	6.77e-05	0.000207	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Prednisone—hematologic cancer	6.75e-05	0.000206	CcSEcCtD
Fosamprenavir—Nausea—Prednisolone—hematologic cancer	6.75e-05	0.000206	CcSEcCtD
Fosamprenavir—Myalgia—Epirubicin—hematologic cancer	6.74e-05	0.000206	CcSEcCtD
Fosamprenavir—Pruritus—Betamethasone—hematologic cancer	6.71e-05	0.000205	CcSEcCtD
Fosamprenavir—Pruritus—Dexamethasone—hematologic cancer	6.71e-05	0.000205	CcSEcCtD
Fosamprenavir—Skin disorder—Methotrexate—hematologic cancer	6.7e-05	0.000205	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.69e-05	0.000205	CcSEcCtD
Fosamprenavir—Vomiting—Triamcinolone—hematologic cancer	6.64e-05	0.000203	CcSEcCtD
Fosamprenavir—Rash—Triamcinolone—hematologic cancer	6.59e-05	0.000201	CcSEcCtD
Fosamprenavir—Dermatitis—Triamcinolone—hematologic cancer	6.58e-05	0.000201	CcSEcCtD
Fosamprenavir—Anorexia—Methotrexate—hematologic cancer	6.58e-05	0.000201	CcSEcCtD
Fosamprenavir—Headache—Triamcinolone—hematologic cancer	6.55e-05	0.0002	CcSEcCtD
Fosamprenavir—Body temperature increased—Prednisone—hematologic cancer	6.53e-05	0.0002	CcSEcCtD
Fosamprenavir—Abdominal pain—Prednisone—hematologic cancer	6.53e-05	0.0002	CcSEcCtD
Fosamprenavir—Diarrhoea—Dexamethasone—hematologic cancer	6.49e-05	0.000198	CcSEcCtD
Fosamprenavir—Diarrhoea—Betamethasone—hematologic cancer	6.49e-05	0.000198	CcSEcCtD
Fosamprenavir—Nervous system disorder—Epirubicin—hematologic cancer	6.33e-05	0.000194	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Methotrexate—hematologic cancer	6.29e-05	0.000192	CcSEcCtD
Fosamprenavir—Skin disorder—Epirubicin—hematologic cancer	6.27e-05	0.000192	CcSEcCtD
Fosamprenavir—Dizziness—Dexamethasone—hematologic cancer	6.27e-05	0.000192	CcSEcCtD
Fosamprenavir—Dizziness—Betamethasone—hematologic cancer	6.27e-05	0.000192	CcSEcCtD
Fosamprenavir—Myalgia—Doxorubicin—hematologic cancer	6.23e-05	0.000191	CcSEcCtD
Fosamprenavir—Nausea—Triamcinolone—hematologic cancer	6.21e-05	0.00019	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.19e-05	0.000189	CcSEcCtD
Fosamprenavir—Anorexia—Epirubicin—hematologic cancer	6.15e-05	0.000188	CcSEcCtD
Fosamprenavir—Hypersensitivity—Prednisone—hematologic cancer	6.08e-05	0.000186	CcSEcCtD
Fosamprenavir—Vomiting—Dexamethasone—hematologic cancer	6.03e-05	0.000184	CcSEcCtD
Fosamprenavir—Vomiting—Betamethasone—hematologic cancer	6.03e-05	0.000184	CcSEcCtD
Fosamprenavir—Decreased appetite—Methotrexate—hematologic cancer	6e-05	0.000183	CcSEcCtD
Fosamprenavir—Rash—Dexamethasone—hematologic cancer	5.98e-05	0.000183	CcSEcCtD
Fosamprenavir—Rash—Betamethasone—hematologic cancer	5.98e-05	0.000183	CcSEcCtD
Fosamprenavir—Dermatitis—Betamethasone—hematologic cancer	5.97e-05	0.000183	CcSEcCtD
Fosamprenavir—Dermatitis—Dexamethasone—hematologic cancer	5.97e-05	0.000183	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.96e-05	0.000182	CcSEcCtD
Fosamprenavir—Fatigue—Methotrexate—hematologic cancer	5.95e-05	0.000182	CcSEcCtD
Fosamprenavir—Headache—Betamethasone—hematologic cancer	5.94e-05	0.000182	CcSEcCtD
Fosamprenavir—Headache—Dexamethasone—hematologic cancer	5.94e-05	0.000182	CcSEcCtD
Fosamprenavir—Asthenia—Prednisone—hematologic cancer	5.92e-05	0.000181	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.88e-05	0.00018	CcSEcCtD
Fosamprenavir—Nervous system disorder—Doxorubicin—hematologic cancer	5.86e-05	0.000179	CcSEcCtD
Fosamprenavir—Pruritus—Prednisone—hematologic cancer	5.84e-05	0.000179	CcSEcCtD
Fosamprenavir—Skin disorder—Doxorubicin—hematologic cancer	5.8e-05	0.000177	CcSEcCtD
Fosamprenavir—Anorexia—Doxorubicin—hematologic cancer	5.69e-05	0.000174	CcSEcCtD
Fosamprenavir—Diarrhoea—Prednisone—hematologic cancer	5.65e-05	0.000173	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Methotrexate—hematologic cancer	5.64e-05	0.000173	CcSEcCtD
Fosamprenavir—Nausea—Dexamethasone—hematologic cancer	5.63e-05	0.000172	CcSEcCtD
Fosamprenavir—Nausea—Betamethasone—hematologic cancer	5.63e-05	0.000172	CcSEcCtD
Fosamprenavir—Decreased appetite—Epirubicin—hematologic cancer	5.61e-05	0.000172	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.57e-05	0.00017	CcSEcCtD
Fosamprenavir—Fatigue—Epirubicin—hematologic cancer	5.57e-05	0.00017	CcSEcCtD
Fosamprenavir—Dizziness—Prednisone—hematologic cancer	5.46e-05	0.000167	CcSEcCtD
Fosamprenavir—Body temperature increased—Methotrexate—hematologic cancer	5.45e-05	0.000167	CcSEcCtD
Fosamprenavir—Abdominal pain—Methotrexate—hematologic cancer	5.45e-05	0.000167	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5.44e-05	0.000166	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Epirubicin—hematologic cancer	5.28e-05	0.000161	CcSEcCtD
Fosamprenavir—Vomiting—Prednisone—hematologic cancer	5.25e-05	0.00016	CcSEcCtD
Fosamprenavir—Rash—Prednisone—hematologic cancer	5.21e-05	0.000159	CcSEcCtD
Fosamprenavir—Dermatitis—Prednisone—hematologic cancer	5.2e-05	0.000159	CcSEcCtD
Fosamprenavir—Decreased appetite—Doxorubicin—hematologic cancer	5.19e-05	0.000159	CcSEcCtD
Fosamprenavir—Headache—Prednisone—hematologic cancer	5.17e-05	0.000158	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.16e-05	0.000158	CcSEcCtD
Fosamprenavir—Fatigue—Doxorubicin—hematologic cancer	5.15e-05	0.000157	CcSEcCtD
Fosamprenavir—Body temperature increased—Epirubicin—hematologic cancer	5.1e-05	0.000156	CcSEcCtD
Fosamprenavir—Abdominal pain—Epirubicin—hematologic cancer	5.1e-05	0.000156	CcSEcCtD
Fosamprenavir—Hypersensitivity—Methotrexate—hematologic cancer	5.08e-05	0.000155	CcSEcCtD
Fosamprenavir—Asthenia—Methotrexate—hematologic cancer	4.95e-05	0.000151	CcSEcCtD
Fosamprenavir—Nausea—Prednisone—hematologic cancer	4.9e-05	0.00015	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.89e-05	0.000149	CcSEcCtD
Fosamprenavir—Pruritus—Methotrexate—hematologic cancer	4.88e-05	0.000149	CcSEcCtD
Fosamprenavir—Hypersensitivity—Epirubicin—hematologic cancer	4.76e-05	0.000145	CcSEcCtD
Fosamprenavir—Abdominal pain—Doxorubicin—hematologic cancer	4.72e-05	0.000144	CcSEcCtD
Fosamprenavir—Body temperature increased—Doxorubicin—hematologic cancer	4.72e-05	0.000144	CcSEcCtD
Fosamprenavir—Diarrhoea—Methotrexate—hematologic cancer	4.72e-05	0.000144	CcSEcCtD
Fosamprenavir—Asthenia—Epirubicin—hematologic cancer	4.63e-05	0.000142	CcSEcCtD
Fosamprenavir—Pruritus—Epirubicin—hematologic cancer	4.57e-05	0.00014	CcSEcCtD
Fosamprenavir—Dizziness—Methotrexate—hematologic cancer	4.56e-05	0.00014	CcSEcCtD
Fosamprenavir—Diarrhoea—Epirubicin—hematologic cancer	4.42e-05	0.000135	CcSEcCtD
Fosamprenavir—Hypersensitivity—Doxorubicin—hematologic cancer	4.4e-05	0.000135	CcSEcCtD
Fosamprenavir—Vomiting—Methotrexate—hematologic cancer	4.39e-05	0.000134	CcSEcCtD
Fosamprenavir—Rash—Methotrexate—hematologic cancer	4.35e-05	0.000133	CcSEcCtD
Fosamprenavir—Dermatitis—Methotrexate—hematologic cancer	4.35e-05	0.000133	CcSEcCtD
Fosamprenavir—Headache—Methotrexate—hematologic cancer	4.32e-05	0.000132	CcSEcCtD
Fosamprenavir—Asthenia—Doxorubicin—hematologic cancer	4.29e-05	0.000131	CcSEcCtD
Fosamprenavir—Dizziness—Epirubicin—hematologic cancer	4.27e-05	0.000131	CcSEcCtD
Fosamprenavir—Pruritus—Doxorubicin—hematologic cancer	4.23e-05	0.000129	CcSEcCtD
Fosamprenavir—Vomiting—Epirubicin—hematologic cancer	4.11e-05	0.000126	CcSEcCtD
Fosamprenavir—Nausea—Methotrexate—hematologic cancer	4.1e-05	0.000125	CcSEcCtD
Fosamprenavir—Diarrhoea—Doxorubicin—hematologic cancer	4.09e-05	0.000125	CcSEcCtD
Fosamprenavir—Rash—Epirubicin—hematologic cancer	4.07e-05	0.000124	CcSEcCtD
Fosamprenavir—Dermatitis—Epirubicin—hematologic cancer	4.07e-05	0.000124	CcSEcCtD
Fosamprenavir—Headache—Epirubicin—hematologic cancer	4.05e-05	0.000124	CcSEcCtD
Fosamprenavir—Dizziness—Doxorubicin—hematologic cancer	3.95e-05	0.000121	CcSEcCtD
Fosamprenavir—Nausea—Epirubicin—hematologic cancer	3.84e-05	0.000117	CcSEcCtD
Fosamprenavir—Vomiting—Doxorubicin—hematologic cancer	3.8e-05	0.000116	CcSEcCtD
Fosamprenavir—Rash—Doxorubicin—hematologic cancer	3.77e-05	0.000115	CcSEcCtD
Fosamprenavir—Dermatitis—Doxorubicin—hematologic cancer	3.76e-05	0.000115	CcSEcCtD
Fosamprenavir—Headache—Doxorubicin—hematologic cancer	3.74e-05	0.000114	CcSEcCtD
Fosamprenavir—Nausea—Doxorubicin—hematologic cancer	3.55e-05	0.000109	CcSEcCtD
